Wide areas of the pharmaceutical industry are ripe for enhancement, as examples from the industry’s top innovators reflect.

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

US President Donald Trump kicked off his second term with a series of directives aimed at the US National Institutes of ...

SmartCella has secured exclusive rights to advance research around cell replacement therapies for the treatment of ...

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...

Speaking publicly for the first time about the USAID freeze, WHO director-general Dr Tedros has asked the US to reconsider ...

AbbVie has entered a partnership and option-to-license agreement with Xilio for tumour-activated, antibody-based ...

TriNetX has collaborated with Fujitsu to establish TriNetX Japan KK, a JV aimed at accelerating healthcare research and ...

Trump's tariffs will not only impact sponsors, but higher costs will ripple down the clinical trial supply chain in the US.

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...

Lundbeck has received the US FDA fast track designation for amlenetug, a potential treatment for multiple system atrophy (MSA ...